CCO Conference Highlights of ASCO GU 2020

February 13-15, 2020; San Francisco, California
Download this summary slideset that includes key data from studies of genitourinary cancers from the 2020 annual meeting in San Francisco.
Format: Microsoft PowerPoint (.ppt)
File Size: 645 KB
Released: February 28, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Multidisciplinary commentary on optimal use of HER2-targeted treatment in early and metastatic breast cancer, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP Released: May 10, 2022

Two expert thoracic oncologists discuss novel anti-TIGIT immunotherapies for treatment of NSCLC, from Clinical Care Options (CCO)

person default Ani Balmanoukian, MD person default Jyoti D. Patel, MD Released: May 3, 2022

Diwakar Davar, MD, and Jyoti D. Patel, MD, discuss the role of TIGIT and emerging therapies for targeting TIGIT, including current trial data, from Clinical Care Options (CCO)

person default Diwakar Davar, MD person default Jyoti D. Patel, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 27, 2022 Expired: April 26, 2023

Diwakar Davar, MD, and Jyoti D. Patel, MD, review the role of TIGIT and investigational therapies being evaluated in solid tumors, from Clinical Care Options (CCO)

person default Diwakar Davar, MD person default Jyoti D. Patel, MD Released: April 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings